Skip to main content
Fig. 2 | Trials

Fig. 2

From: Evaluation of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, and inflammatory and antioxidant biomarkers in overweight or obese prediabetic patients: a study protocol for a randomized double-blind placebo-controlled phase 2 clinical trial

Fig. 2

Schedule of enrollment, interventions, and assessments. ABSI, A Body Shape Index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BCM, beta cell function; BMI, body mass index; DBP, diastolic blood pressure; FFM, free fat mass; FM, fat mass; FPG, fasting plasma glucose; HC, hip circumference; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein cholesterol; HOMA, homeostasis model of assessment; HRQOL, health-related quality of life; hs-CRP, high-sensitivity C-reactive protein; IL-1B, interleukin-B; IPAQ-SF, Short Form of International Physical Activity Questionnaire; IR, insulin resistance; IS, insulin sensitivity; LDL, low-density lipoprotein cholesterol; MDA, malondialdehyde; MM, muscle mass; HTN, hypertension; SBP, systolic blood pressure; TAC, total blood antioxidant capacity; TTC, total cholesterol; TG, triglycerides; VLDL, very low-density lipoprotein; WC, waist circumference; WHR, waist-hip ratio; WHtR, waist-height ratio; 2hpp, 2 h post-prandial

Back to article page

Trials

ISSN: 1745-6215